Let’s Take a Fresh Look at: Abbott Laboratories (NYSE: ABT)

On 04 Feb 2020, Abbott Laboratories (NYSE: ABT) changed 1.34% to recent value of $88.23. The stock transacted 3385849 shares during most recent day however it has an average volume of 4855.84K shares. It spotted trading -4.56% off 52-week high price. On the other end, the stock has been noted 23.40% away from the low price over the last 52-weeks.

Abbott (ABT) recently reported that the U.S. Food and Drug Administration (FDA) has accepted a new trial designed to assess its Amplatzer™ Amulet™ Left Atrial Appendage Occluder for people with atrial fibrillation (AF) – a condition in which the normal rhythm of the heart’s upper chambers is disrupted and becomes erratic – who are at risk of stroke. The CATALYST trial is the first-ever clinical trial comparing the effectiveness of a left atrial appendage (LAA) closure device to a newer class of blood thinners, known as non-vitamin K antagonist oral anticoagulant (NOAC) drugs, which are presently the standard treatment option for AF.

“A device that can address a important structural issue of the heart via a minimally invasive procedure would be a important step forward for patients with atrial fibrillation eligible for long-term NOAC therapy,” stated Vivek Reddy, M.D., director of Cardiac Arrhythmia Services for The Mount Sinai Hospital in New York and the principal investigator for the CATALYST trial. “This study is an extremely important step in assessing the Amplatzer Amulet as an effective non-prescription drug alternative for patients with AF who are at a raised risk for ischemic stroke.”

The Amplatzer Amulet device received CE Mark authorization in 2013 and is accessible in Europe and other countries that recognize CE Mark. At this time, the device is for investigational use only in the U.S.

“We are focused on expanding access to minimally invasive options for structural heart disease through new clinical data,” stated Neil Moat, M.D., chief medical officer of Abbott’s structural heart business. “The CATALYST trial has the potential to provide data for the Amplatzer Amulet LAA Occluder that could change clinical practice by eliminating a lifetime need for blood thinners – reinforcing our mission of helping people live better lives through better health.”

ABT has a gross margin of 58.60% and an operating margin of 12.40% while its profit margin remained 9.10% for the last 12 months. Its earnings per share (EPS) expected to touch remained 34.30% for this year while earning per share for the next 5-years is expected to reach at 11.08%.  The company has 1809.45M of outstanding shares and 1755.94M shares were floated in the market. According to the most recent quarter its current ratio was 1.5 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.26% from the mean of 20 days, 1.82% from mean of 50 days SMA and performed 5.83% from mean of 200 days price. Company’s performance for the week was -1.46%, 2.72% for month and YTD performance remained 1.58%.

 

Mary Smith

Mary Smith– Health Industry My Name is Mary Smith, and I am 29 years old who is an industrialist other than a writer. I want to catch the attention of my audience and publishers without sounds too dry and dull. I am that sort of person who adores his spare time by writing my thoughts and ideas for my audience or readers. My writing skills are not confined to any specific field, I wrote on many topics, but healthcare sector and Stock Market articles are always my favorite. I love to express myself by creative modes such as drawing, singing, and writing. I love to spend my leisure time with my beloved cat, sleep or by playing my favorite video games.

Leave a Reply

Your email address will not be published. Required fields are marked *